Last reviewed · How we verify

At least one dose of HAV

LiuZhou People's Hospital · FDA-approved active Biologic Quality 5/100

At least one dose of HAV is a Biologic drug developed by LiuZhou People's Hospital. It is currently FDA-approved.

At a glance

Generic nameAt least one dose of HAV
SponsorLiuZhou People's Hospital
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about At least one dose of HAV

What is At least one dose of HAV?

At least one dose of HAV is a Biologic drug developed by LiuZhou People's Hospital.

Who makes At least one dose of HAV?

At least one dose of HAV is developed and marketed by LiuZhou People's Hospital (see full LiuZhou People's Hospital pipeline at /company/liuzhou-people-s-hospital).

What development phase is At least one dose of HAV in?

At least one dose of HAV is FDA-approved (marketed).

Related